Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KarXT + KarX-EC for cognitive impairment in Alzheimer's disease
NL-OMON58814Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of xanomeline in Alzheimer's disease (AD), sponsored by Bristol Myers Squibb. Primary endpoints: Change from baseline in ADAS-Cog11 at Week 24 and CIBIC+ at Week 24. Started Nov 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON58814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58814.